Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0581 has been discontinued.
View all Adrenergic α<sub>1</sub> Receptors products.Very potent ligand for α1 sites (Ki for displacement of prazosin = 0.2 nM). Displays different binding properties for each α1 subtype (pKi values are 8.74, 9.44 and 9.57 for α1B, α1D and α1A adrenoceptors respectively). Also binds to 5-HT1A sites (Ki = 50 nM).
分子量 | 419.48 |
公式 | C23H25N5O3 |
储存 | Store at RT |
CAS Number | 133399-65-2 |
PubChem ID | 4013695 |
InChI Key | AQASGOHUMGAWJJ-UHFFFAOYSA-N |
Smiles | COC1=C(C=CC=C1)N1CCN(CCN2C(=O)NC3=C(NC4=CC=CC=C34)C2=O)CC1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Russo et al (1991) Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective α1 adrenoceptor ligands. J.Med.Chem. 34 1850 PMID: 1648138
Romeo et al (2003) New pyrimido[5,4-b]indoles as ligands for α1-adrenoceptor subtypes. J.Med.Chem. 46 2877 PMID: 12825930
关键词: 3-MPPI, 3-MPPI supplier, 5-HT1A, ligand, α1-adrenoceptor, alpha1-adrenoceptor, a1-adrenoceptor, Serotonin, Receptors, 5-HT1, α1-adrenergic, alpha1-adrenergic, a1-adrenergic, Adrenergic, Alpha-1, 0581, Tocris Bioscience
目前没有该产品的评论。 Be the first to review 3-MPPI and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.